We recently demonstrated that targeting VEGF-A is sufficient to modulate Treg proportion and number in cancer since anti-VEGF-A antibody (in mice) or bevacizumab (in humans) inhibits Treg increase in a mouse model of colorectal cancer and in metastatic colorectal cancer patients, respectively [23]. The gene discussed is VEGFA; the disease is colorectal cancer.